INTENSITY THERAPEUTICS, INC.
No enriched coverage for $INTS in the last 7 days.
No SEC Form 4 filings for $INTS in the last 30 days.
See all $INTS insider activity →INTENSITY THERAPEUTICS, INC. (INTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 • Patien
INTENSITY THERAPEUTICS, INC. (INTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. intensity-20260616 0001567264 FALSE 0001567264 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event repor
Intensity Therapeutics (INTS) has increased its at-the-market (ATM) offering capacity to $60.0 million to improve its financial flexibility. This allows the company to issue common stock, though it is not obligated to sell shares, maintaining discretion based on market conditions and strategy. The ATM program is conducted with H.C. Wainwright & Co. as the sales agent, as detailed in an SEC filing from March 23, 2026.
Recent INTS coverage spans financial news, earnings and corporate actions.
The filing is a near-term catalyst for trial execution and cash runway, with early Phase 2 efficacy signals supporting risk-on sentiment.
The filing confirms shareholder approval of equity plan amendments and ratification of the auditor, with no operational or financial guidance changes disclosed.
Intensity Therapeutics has expanded its ATM offering to $60 million, providing financial flexibility. This move may support future growth initiatives but does not directly impact current operations or stock valuation.
Intensity Therapeutics has increased its ATM capacity by $60 million, providing financial flexibility. The news suggests a potential for future equity issuance, which could dilute existing shares but also indicates strategic growth plans.
The company's increase in ATM capacity signals an intent to raise additional capital, potentially diluting existing shares but also providing funds for future growth. The immediate market reaction appears neutral, with a slight positive sentiment.
alphai scores every news story that mentions INTS with an AI model for sentiment and relevance, and aggregates insider trades from INTENSITY THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
INTENSITY THERAPEUTICS, INC. (INTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 • Patien
4 min readINTENSITY THERAPEUTICS, INC. (INTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. intensity-20260616 0001567264 FALSE 0001567264 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event repor
2 min readIntensity Therapeutics (INTS) has increased its at-the-market (ATM) offering capacity to $60.0 million to improve its financial flexibility. This allows the company to issue common stock, though it is not obligated to sell shares, maintaining discretion based on market conditions and strategy. The ATM program is conducted with H.C. Wainwright & Co. as the sales agent, as detailed in an SEC filing from March 23, 2026.
2 min readIntensity Therapeutics, Inc. has increased its at-the-market (ATM) stock offering program capacity to $60.0 million. This expansion provides the company with greater financial flexibility to raise equity capital through the sale of common shares via H.C. Wainwright & Co. LLC, although the company is not obligated to issue any shares. The decision to utilize the ATM program will depend on market conditions and the company's strategic priorities.
2 min readIntensity Therapeutics (NASDAQ:INTS) has increased its At-The-Market (ATM) offering capacity to $60 million, effective March 23, 2026, by supplementing its July 11, 2024 sales agreement. The company has already sold 1,297,655 shares under the previous agreement, totaling $12,029,360 in gross sales. H.C. Wainwright & Co., LLC continues to act as the agent for the ATM offering, with all other terms of the agreement remaining unchanged.
2 min readIntensity Therapeutics Inc. ( NASDAQ:INTS ) shares are trending on Friday. Check out the current price of INTS stock here.
3 min readU.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.03% to 47,644.08 while the NASDAQ fell 1.13% to 23,687.37. The S&P 500 also fell, dropping, 0.63% to 6,847.40.
4 min readSHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc.
2 min readIntensity Therapeutics ( NASDAQ:INTS ) , a clinical-stage biotechnology company focused on direct tumor-targeted treatments, released its second quarter 2025 earnings on August 7, 2025. The quarter's headline news is a significant reduction in operating expenses, achieved while maintaining ...
2 min readIntensity Therapeutics shares are trading lower by 34.9% during Friday's session. The company announced the pricing of a public offering expected to raise approximately $2.35 million. Don't face extreme market conditions unprepared.
3 min read
